Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

SRL India and Onko_Sure...And the beat goes on...Still selling Onko-Sure in 2015


Radient Pharmaceuticals (AMEX:RPC) has secured a major new partnership with Super Religare Laboratories in India for the distribution of its Onko-Sure diagnostics test kits.

http://www.proactiveinvestors.com/companies/news/15356/radient-secures-distribution-deal-for-onko-sure-tests-in-india-shares-rally-15356.html


Patients - Metropolis India

www.metropolisindia.com/patients - View by Ixquick Proxy - Highlight

Metropolis Healthcare, the specialist in women wellness is proud to present ... cleared in vitro diagnostic (IVD) blood-marker test known as Onko-Sure®. ... Metropolis is India's only laboratory to have built an in-house efficient customer care ...


http://www.metropolisindia.com/patients/cancer-eight



http://www.srlworld.com/wellness/content/160/niche-wellness-test.html



http://www.uptodate.com/contents/surveillance-after-colorectal-cancer-resectionurveillance after colorectal cancer resection

Authors
Beverly Moy, MD, MPH
Francis A Farraye, MD, MSc
Brian C Jacobson, MD, MPH
Section Editors
Kenneth K Tanabe, MD
Richard M Goldberg, MD
Deputy Editor
Diane MF Savarese, MD

Disclosures: Beverly Moy, MD, MPH Consultant/Advisory Boards (spouse/partner): Motus GI [Survival after CRC resection (Bowel preparation)]; Olympus [Survival after CRC resection (Endoscopy equipment)]. Francis A Farraye, MD, MSc Nothing to disclose. Brian C Jacobson, MD, MPH Consultant/Advisory Boards: Olympus [Colonoscopy (colonoscopes)]; Motus GI [Colonoscopes (equipment for bowel preparation)]. Kenneth K Tanabe, MD Consultant/Advisory Boards: Astellas [hepatocellular carcinoma (enzalutamide)]. Patent Holder (no licenses/royalties to date): EGF SNP to determine risk for HCC (cirrhosis, hepatocellular carcinoma); Use of EGFR inhibitors to prevent HCC (cirrhosis, hepatocellular carcinoma). Richard M Goldberg, MD Grant/Research/Clinical Trial Support: Sanofi [Colon cancer (Afibercept)]; Bayer [Colon cancer (Regorafinib)]; Medimmune [Colon cancer (Experimental agent)]; Merck [Colon cancer (PD-1 inhibitor MK-3475)]; Kanghong [Colon cancer (Experimental drug)]; Biothera [Colon cancer (Data Safety Monitoring Committee Chair for a phase III trial)]; Baxter [Colon cancer (Experimental drug)]; Taiho [Colon cancer (Experimental drug)]; Lilly [Colon cancer (Ramicurimab)]. Diane MF Savarese, MD Nothing to disclose.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

Conflict of interest policy
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Feb 2015. | This topic last updated: Jan 19, 2015.

Thus, use of the Onko-Sure assay could be considered for patients with initially low CEA levels. One of the advantages of the DR-70 assay, which measures fibrin and fibrinogen degradation products (collectively referred to as FDP) in the serum, is that the antigen is freely diffusible in the blood compared with CEA, which is normally attached to cancer cells due to its role as an adhesion molecule.

However, as with CEA, an elevated DR-70 assay value should not be interpreted as absolute evidence for the presence of disease recurrence, since a small percentage of healthy individuals as well as those with non-malignant conditions (pancreatic disease, heart disease, coagulation disorders, acute infection, or trauma) and malignancy at other sites have elevations in DR-70.

http://www.uptodate.com/contents/surveillance-after-colorectal-cancer-resection